About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Celadon Pharmaceuticals Reaffirms Commitment to Patient Centred Innovation in Cannabis Based Medicines

Celadon Pharmaceuticals reaffirms its patient-centred approach, advancing cannabis-based medicines through innovation, regulatory excellence, and MHRA-licensed research. Focused on limited-treatment conditions, the UK company aims to deliver safe, effective, evidence-based therapies that improve patients’ quality of life.

-- Celadon Pharmaceuticals, a leading British pharmaceutical company dedicated to advancing cannabis-based medicines, today reaffirmed its commitment to placing patients at the heart of its research and development strategy.

The company continues to concentrate its R&D efforts on key therapeutic areas where patients face limited treatment options. By leveraging its MHRA licensed facility and pharmaceutical expertise, Celadon is advancing the understanding of how cannabinoids can play a transformative role in modern medicine.

“Celadon’s mission has always been defined by patient impact rather than market noise,” said a company spokesperson. “Our focus remains on science, innovation and the responsible development of therapies that can improve lives.”

Celadon’s state-of-the-art facility provides a robust platform for pharmaceutical-grade research and development, underpinned by a team of specialists working to the highest standards of safety and compliance. This capability reinforces the company’s role as a frontrunner in the evolving UK cannabis medicines sector.

While recognising the challenges faced across the wider life sciences landscape, Celadon maintains that innovation, regulatory excellence and patient outcomes remain at the core of its operations. By focusing on advancing cannabinoid science, the company continues to strengthen its position as a trusted innovator.

“As the landscape for cannabis-based medicines develops, our priority is to ensure patients benefit from therapies that are accessible, effective and evidence-based,” the spokesperson added. “Celadon is uniquely positioned to help shape the future of this important sector.”

Celadon Pharmaceuticals remains steadfast in its mission: improving quality of life for patients most in need by developing breakthrough cannabis-based medicines.

About Celadon Pharmaceuticals

Celadon Pharmaceuticals is a UK based pharmaceutical company focused on the research, development and production of cannabis-based medicines. Operating from an MHRA licensed facility, Celadon is committed to advancing safe, effective and evidence based therapies for conditions where patients face limited treatment options. With a strong emphasis on regulatory compliance, innovation and patient outcomes, Celadon is recognised as one of the leading innovators shaping the future of cannabinoid-based medicine in the UK.

Contact Info:
Name: Press and Media
Email: Send Email
Organization: Celadon Pharmaceuticals
Website: https://celadonpharma.com/

Release ID: 89168518

In case of identifying any errors, concerns, or inconsistencies within the content shared in this press release that necessitate action or if you require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team is committed to addressing your concerns within 8 hours by taking necessary actions diligently to rectify any identified issues or supporting you with the removal process. Delivering accurate and reliable information remains our top priority.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.